Literature DB >> 11189691

Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

A B Miller1, S Yurgalevitch, J L Weissfeld.   

Abstract

The procedures that have been adopted in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial are described. These procedures have been designed to ensure unbiased decisions on the underlying cause of death for all confirmed or suspected PLCO cancers. A death review committee with a nonvoting chair and three experienced reviewers as members has been appointed. After an initial pilot study, the procedures have been instituted and are working well.

Entities:  

Mesh：

Year:  2000        PMID： 11189691     DOI： 10.1016/s0197-2456(00)00095-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


  32 in total

1.  Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.

Authors:  Amanda I Phipps; Michael N Passarelli; Andrew T Chan; Tabitha A Harrison; Jihyoun Jeon; Carolyn M Hutter; Sonja I Berndt; Hermann Brenner; Bette J Caan; Peter T Campbell; Jenny Chang-Claude; Stephen J Chanock; Jeremy P Cheadle; Keith R Curtis; David Duggan; David Fisher; Charles S Fuchs; Manish Gala; Edward L Giovannucci; Richard B Hayes; Michael Hoffmeister; Li Hsu; Eric J Jacobs; Lina Jansen; Richard Kaplan; Elisabeth J Kap; Timothy S Maughan; John D Potter; Robert E Schoen; Daniela Seminara; Martha L Slattery; Hannah West; Emily White; Ulrike Peters; Polly A Newcomb
Journal:  Carcinogenesis       Date:  2015-11-19       Impact factor: 4.944

Review 2.  Design of cancer screening trials/randomized trials for evaluation of cancer screening.

Authors:  Anthony B Miller
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Lethal Prostate Cancer in the PLCO Cancer Screening Trial.

Authors:  Jonathan Shoag; Sameer Mittal; Joshua A Halpern; Douglas Scherr; Jim C Hu; Christopher E Barbieri
Journal:  Eur Urol       Date:  2016-05-07       Impact factor: 20.096

4.  Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study.

Authors:  Scott P Kelly; Hannah Lennon; Matthew Sperrin; Charles Matthews; Neal D Freedman; Demetrius Albanes; Michael F Leitzmann; Andrew G Renehan; Michael B Cook
Journal:  Int J Epidemiol       Date:  2019-04-01       Impact factor: 7.196

5.  Prediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer risk.

Authors:  Martha M Sklavos; Cindy Ke Zhou; Ligia A Pinto; Michael B Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-26       Impact factor: 4.254

6.  Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.

Authors:  Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer.

Authors:  Robert E Schoen; Anthony Razzak; Kelly J Yu; Sonja I Berndt; Kevin Firl; Thomas L Riley; Paul F Pinsky
Journal:  Gastroenterology       Date:  2015-08-05       Impact factor: 22.682

9.  Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project.

Authors:  V Paul Doria-Rose; Pamela M Marcus
Journal:  Lung Cancer       Date:  2008-06-30       Impact factor: 5.705

10.  A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Bríd M Ryan; Sharon R Pine; Anil K Chaturvedi; Neil Caporaso; Curtis C Harris
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.